Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
21/26/21	SEK 0.4300	-4.02%	50,73,914
18/26/18	SEK 0.4480	+7.31%	37,80,673
17/26/17	SEK 0.4175	-8.74%	51,48,576
16/26/16	SEK 0.4575	-0.33%	17,68,715
15/26/15	SEK 0.4590	-1.18%	29,06,802

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 21/09/2026 pm IST			5-day change	1st Jan Change
0.4300 ^SEK	-4.02%		-8.61%	-48.13%

11/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW

Market Cap	8.71Cr 88.6L 77.25L 72.76L 66.26L 1.24Cr 85Cr 1.24Cr 3.36Cr 43Cr 3.33Cr 3.25Cr 139.53Cr	P/E 2026 *	-1.59x	P/E 2027 *	-1.13x
Enterprise Value	7.11Cr 72.33L 63.07L 59.4L 54.09L 1.01Cr 69Cr 1.02Cr 2.74Cr 35Cr 2.72Cr 2.66Cr 113.91Cr	EV / Sales 2026 *	2.27x	EV / Sales 2027 *	-
Free-Float	46.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
CBOE		Real-time
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time

11/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
11/09	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
11/09	Asker plunges on choppy Stockholm market	FW
11/09	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
11/09	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101	CI
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

10:43pm	Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need	GL
18/09	Alzinova publishes information memorandum in connection with rights issue of units	AQ
11/09	Alzinova: Phase II study update and SEK51 rights issue	AQ
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
11/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ

1 day	-4.02%
1 week	-8.61%
Current month	-46.25%
1 month	-47.50%
3 months	-10.32%
6 months	-28.45%
Current year	-48.13%

1 week	0.4	0.47
1 month	0.4	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-4.02%	-8.61%	-62.54%	-86.50%	92.05L
LONZA GROUP AG	+0.59%	+3.31%	+1.03%	+24.53%	4.63TCr
IQVIA HOLDINGS INC.	+1.30%	+3.10%	+44.15%	+31.38%	4.39TCr
REVOLUTION MEDICINES, INC.	+0.95%	-5.40%	+342.72%	+548.37%	4.09TCr
BEONE MEDICINES AG	+4.23%	+5.53%	+9.35%	+89.62%	3.99TCr
CELLTRION, INC.	+1.11%	+1.80%	+11.52%	+43.15%	2.95TCr
MEDPACE HOLDINGS, INC.	+1.94%	+6.24%	+25.19%	+145.07%	1.71TCr
ASCENDIS PHARMA A/S	+0.37%	-9.84%	-	-	1.55TCr
EUROFINS SCIENTIFIC SE	+2.12%	+10.41%	+24.78%	+39.05%	1.52TCr
TEMPUS AI, INC.	+0.24%	+32.23%	-11.57%	-	1.4TCr
Average	+0.91%	+3.10%	+42.74%	+104.33%	2.62TCr
Weighted average by Cap.	+1.59%	+2.08%	+70.37%	+141.24%

	2026 *	2027 *
Net sales	3.14Cr 31.88L 27.79L 26.18L 23.84L 44.7L 31Cr 44.75L 1.21Cr 16Cr 1.2Cr 1.17Cr 50Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.33Cr -6L -17.15L -2.21Cr -17L -16.62L -7.13Cr	-7.7Cr -78.3L -68.27L -64.3L -58.55L -1.1Cr -75Cr -1.1Cr -2.97Cr -38Cr -2.94Cr -2.88Cr -123.3Cr
Net Debt	-1.6Cr -16.27L -14.19L -13.36L -12.17L -22.81L -16Cr -22.84L -61.67L -7.94Cr -61.11L -59.76L -26Cr	-1.9Cr -19.32L -16.84L -15.87L -14.45L -27.09L -19Cr -27.12L -73.23L -9.43Cr -72.57L -70.96L -30Cr